罗沙司他对老年慢性肾衰竭合并肾性贫血患者的疗效及铁代谢的影响

doi:10.3969/j.issn.1671-7171.2025.11.005

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1248 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the therapeutic efficacy of roxadustat on elderly patients with chronic renal failure (CRF) accompanied by renal anemia and its effects on iron metabolism.【Methods】Ninety elderly patients with CRF and renal anemia were randomly divided into a control group and an observation group, with 45 cases in each. The control group received recombinant human erythropoietin (rhEPO) injection therapy, while the observation group was treated with roxadustat capsules. The two groups were compared in terms of clinical efficacy, iron metabolism indicators [serum iron (Fe), ferritin (FER), transferrin (TRF)], anemia-related parameters [hemoglobin (Hb), erythropoietin (EPO), hematocrit (HCT)], inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP)], and incidence of adverse reactions.【Results】After treatment, the total effective rate in the observation group was significantly higher than that in the control group (P<0.05). Serum Fe and TRF levels in the observation group were higher, while FER level was lower than that in the control group (P<0.05). Compared to the control group, the levels of Hb, EPO, and HCT were significantly higher in the observation group (P<0.05),while TNF-α, IL-6, and CRP levels were significantly lower in the observation group (P<0.05). The incidence of adverse reactions showed no significant difference between the two groups (P>0.05).【Conclusion】 Roxadustat can effectively improve iron metabolism and anemia in elderly patients with CRF accompanied by renal anemia and reduce inflammatory responses.

Key words： Kidney Failure, Chronic Anemia Prolyl-Hydroxylase Inhibitors Aged

Received: 18 July 2025

PACS:

R692.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAO Jianbo
	HU Chunyu
	WANG Lixin

Cite this article:

HAO Jianbo,HU Chunyu,WANG Lixin. Therapeutic Efficacy of Roxadustat on Elderly Patients with Chronic Renal Failure Accompanied by Renal Anemia and its Effects on Iron Metabolism[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(11): 1857-1859.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.11.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I11/1857

[1] 赵云艽,邱国萍. 蔗糖铁联合促红细胞生成素治疗慢性肾衰竭患者肾性贫血的临床效果[J].中国医学创新,2023,20(34):54-57.
[2] 刘桂林,任直亲,夏丽萍. 罗沙司他联合rHuEPO治疗老年维持性血液透析伴肾性贫血患者的疗效及对铁代谢的影响[J].老年医学与保健,2024,30(5):1425-1428.
[3] 钟婉平,李爱婷,苏晓燕,等. 罗沙司他与重组人促红素治疗维持性血液透析肾性贫血有效性与经济性评价[J].中国药业,2025,34(2):101-105.
[4] 林宝丽,金利思,陈智. 罗沙司他胶囊治疗慢性肾衰竭维持性血液透析肾性贫血患者的效果[J].中国医药导报,2023,20(1):111-114.
[5] 王海婷,常相帝,高洁,等. 尿毒清联合罗沙司他治疗老年慢性肾衰竭的疗效[J].中国老年学杂志,2025,45(7):1628-1631.
[6] 中国中西医结合学会肾脏疾病专业委员会. 慢性肾衰竭中西医结合诊疗指南[J].河北中医,2016,38(2):313-317.
[7] 王艳艳,王国勤,徐潇漪,等. 罗沙司他治疗老年非透析慢性肾脏病肾性贫血的疗效观察[J].中国中西医结合肾病杂志,2024,25(10):871-874.
[8] 葛丹亘,汤冰倩,许建国. 罗沙司他联合多糖铁复合物治疗老年CKD合并肾性贫血的临床疗效[J].川北医学院学报,2024,39(12):1672-1675.
[9] 林海红,李雪锋,江鑫. 重组人红细胞生成素联合罗沙司他对老年肾性贫血维持血液透析患者铁代谢、炎症和营养状态的影响[J].中国老年学杂志,2024,44(20):4960-4963.
[10] 陈瑞丰,于沛,王志婷,等. 罗沙司他联合多糖铁复合物、生血宁治疗重组人促红素效果不佳的维持性血液透析肾性贫血患者的临床研究[J].中国临床药理学杂志,2024,40(12):1704-1708.
[11] 金文敏,孙治华,柳林伟,等. 罗沙司他与重组人促红素分别联合琥珀酸亚铁治疗血液透析患者肾性贫血疗效的比较[J].西北药学杂志,2024,39(5):174-179.
[12] 赵蕾,张若男,张晓琳,等. 罗沙司他在老年非透析肾性贫血患者中治疗效果及心血管安全性[J].临床军医杂志,2025,53(4):366-370.
[13] 王一郎,王红霞,冯秀芳. 罗沙司他联合重组人促红素治疗慢性肾衰竭合并肾性贫血的临床研究[J].中国医师进修杂志,2024,47(12):1104-1107.
[14] 牛星,王敏. 罗沙司他与重组人促红素治疗老年慢性肾衰竭并肾性贫血患者的疗效比较[J].临床合理用药,2024,17(27):141-144.
[15] 冯小华,孙荣嵘,王婷婷,等. 罗沙司他胶囊治疗慢性肾衰竭肾性贫血老年患者的临床研究[J].中国临床药理学杂志,2021,37(19):2565-2568.